CareDx Inc 2026年季度报告

(Mark One) 8000 Marina Boulevard, 4th FloorBrisbane, California 94005(Address of principal executive offices and zip code)(415) 287-2300(Registrant’s telephone number, including area code)N/A(Former name, former address and former fiscal year, if changed since last report)__________________________________________________ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule12b-2of theExchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. There were 51,659,481 shares of the registrant’s Common Stock issued and outstanding as of April24, 2026. CareDx, Inc.TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial StatementsCondensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive Income (Loss)Condensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and Procedures PART II. OTHER INFORMATION Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regardingour future results of operations and financial position, our business strategy and plans, and our objectives for future operations, areforward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,”“should,” “would,” “project,” “plan,” “target,” “predict,” “expect” and the negative and plural forms of these words and similarexpressions are intended to identify forward-looking statements. “CareDx” or the “Company” or “we” or “us” and “our” as used in the Quarterly Report on Form 10-Q refer to CareDx, Inc. and itssubsidiaries. •our ability to generate revenue and increase the commercial success of our current and future testingservices, products and patient and digital solutions;•our ability to obtain, maintain and expand reimbursement coverage from payers for our current and otherfuture testing services, if any;•our plans and ability to continue updating our testing services, products and patient and digital solutions tomaintain our leading position in transplantation;•the outcome or success of our clinical trial collaborations and registry studies;•the favorable review of our testing services and product offerings, and our future solutions, if any, in peer-reviewed publications;•our ability to obtain additional financing on terms favorable to us, or at all;•our anticipated cash needs and our anticipated uses of our funds, including our estimates regardingoperating expenses and capital requirements;•anticipated trends and challenges in our business and the markets in which we operate;•our dependence on certain of our suppliers, service providers and other distribution partners;•disruptions to our business, including disrupt